insulin lispro low mixture + metformin

**insulin lispro low mixture + metformin** is a fixed combination therapy used primarily for treating type 2 diabetes mellitus in patients who require intensification beyond basal insulin and/or oral antihyperglycemic agents. Insulin lispro low mixture (known as LM25 or Mix 75/25) consists of 75% insulin lispro protamine suspension (an intermediate-acting form) and 25% insulin lispro solution (a rapid-acting form), administered subcutaneously twice daily. Metformin is a first-line oral antihyperglycemic agent. **Mechanism of action:** - *Insulin lispro* is a recombinant insulin analog that binds to the insulin receptor, activating its tyrosine kinase signaling → increases glucose uptake (via GLUT4) in muscle/adipose tissue and reduces hepatic glucose output[4]. LM25 provides both basal and prandial insulin action. - *Metformin* reduces hepatic glucose production and increases insulin sensitivity in peripheral tissues. The combination improves glycemic control (HbA1c and postprandial glucose)[1][2]. Primary indication is **type 2 diabetes mellitus** inadequately controlled with oral therapeutic agents or basal insulin.

Brand names

Mix 75/25

Other names

insulin lispro low mixture + metformininsulin lispro protamine suspension 75% and insulin lispro solution 25% + metformin